• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Sacubitril/valsartan in COVID-19 patients: the need for trials.

作者信息

Acanfora Domenico, Ciccone Marco Matteo, Scicchitano Pietro, Acanfora Chiara, Casucci Gerardo

机构信息

Unit of Internal Medicine, San Francesco Hospital, Viale Europa 21, 82037 Telese Terme, BN, Italy.

Section of Cardiovascular Diseases, Department of Emergency and Organ Transplantation, University of Bari, School of Medicine, Bari, Italy.

出版信息

Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(4):253-254. doi: 10.1093/ehjcvp/pvaa044.

DOI:10.1093/ehjcvp/pvaa044
PMID:32369103
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7239226/
Abstract
摘要

相似文献

1
Sacubitril/valsartan in COVID-19 patients: the need for trials.沙库巴曲缬沙坦用于新冠肺炎患者：开展试验的必要性。
Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(4):253-254. doi: 10.1093/ehjcvp/pvaa044.
2
Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients.中性肽链内切酶抑制剂-血管紧张素II受体阻滞剂组合（沙库巴曲/缬沙坦）：应用于2019冠状病毒病患者的理论依据
Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(3):135-136. doi: 10.1093/ehjcvp/pvaa028.
3
Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial.沙库巴曲缬沙坦在射血分数降低的心力衰竭中的应用：LIFE 试验的原理和设计。
JACC Heart Fail. 2020 Oct;8(10):789-799. doi: 10.1016/j.jchf.2020.05.005. Epub 2020 Jun 10.
4
The Rationale for Angiotensin Receptor Neprilysin Inhibitors in a Multi-Targeted Therapeutic Approach to COVID-19.血管紧张素受体脑啡肽酶抑制剂在 COVID-19 多靶点治疗中的作用。
Int J Mol Sci. 2020 Nov 15;21(22):8612. doi: 10.3390/ijms21228612.
5
Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.血管紧张素受体拮抗剂与中性内肽酶抑制剂联合使用
Circulation. 2016 Mar 15;133(11):1115-24. doi: 10.1161/CIRCULATIONAHA.115.018622.
6
Sacubitril/valsartan and B-type natriuretic peptide value: recalculating route.沙库巴曲缬沙坦与B型利钠肽值：重新计算途径
Eur J Heart Fail. 2020 Jan;22(1):162-163. doi: 10.1002/ejhf.1589. Epub 2019 Aug 13.
7
Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor.沙库巴曲缬沙坦：一种新型血管紧张素受体脑啡肽酶抑制剂。
Indian Heart J. 2018 Jul;70 Suppl 1(Suppl 1):S102-S110. doi: 10.1016/j.ihj.2018.01.002. Epub 2018 Jan 8.
8
Angiotensin Receptor Neprilysin Inhibitor Attenuates Myocardial Remodeling and Improves Infarct Perfusion in Experimental Heart Failure.血管紧张素受体脑啡肽酶抑制剂可减轻实验性心力衰竭中的心肌重构并改善梗死区灌注。
Sci Rep. 2019 Apr 8;9(1):5791. doi: 10.1038/s41598-019-42113-0.
9
Clinical Application of Sacubitril/Valsartan in Heart Failure.沙库巴曲缬沙坦在心力衰竭中的临床应用
Am J Ther. 2021 Apr 8;28(4):e511-e513. doi: 10.1097/MJT.0000000000001340.
10
Targeting the Natriuretic Peptide System to Improve Outcomes: PARADISE Lost or Found.
J Am Coll Cardiol. 2024 Mar 5;83(9):915-917. doi: 10.1016/j.jacc.2024.01.009.

引用本文的文献

1
An overview on the treatments and prevention against COVID-19.关于 COVID-19 的治疗和预防概述。
Virol J. 2023 Feb 8;20(1):23. doi: 10.1186/s12985-023-01973-9.
2
Pharmacological agents modifying the renin angiotensin and natriuretic peptide systems in COVID-19 patients.调节新冠病毒肺炎患者肾素-血管紧张素和利钠肽系统的药物制剂
Wien Klin Wochenschr. 2021 Sep;133(17-18):983-988. doi: 10.1007/s00508-021-01855-6. Epub 2021 Apr 20.
3
Between two storms, vasoactive peptides or bradykinin underlie severity of COVID-19?在两次风暴之间，血管活性肽或缓激肽是 COVID-19 严重程度的基础？
Physiol Rep. 2021 Mar;9(5):e14796. doi: 10.14814/phy2.14796.
4
Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19.科学假说与合理药理学：沙库巴曲缬沙坦在 COVID-19 导致的心脏损伤中的应用。
Med Hypotheses. 2021 Feb;147:110486. doi: 10.1016/j.mehy.2021.110486. Epub 2021 Jan 7.
5
Potential role of interferons in treating COVID-19 patients.干扰素在治疗 COVID-19 患者中的潜在作用。
Int Immunopharmacol. 2021 Jan;90:107171. doi: 10.1016/j.intimp.2020.107171. Epub 2020 Nov 3.
6
Renin-Angiotensin System Inhibitors in COVID-19: Current Concepts.肾素-血管紧张素系统抑制剂在2019冠状病毒病中的应用：当前概念
Int J Hypertens. 2020 Oct 21;2020:1025913. doi: 10.1155/2020/1025913. eCollection 2020.
7
Repurposing of existing FDA approved drugs for Neprilysin inhibition: An study.将现有美国食品药品监督管理局（FDA）批准的药物用于抑制中性肽链内切酶：一项研究。
J Mol Struct. 2021 Jan 15;1224:129073. doi: 10.1016/j.molstruc.2020.129073. Epub 2020 Aug 12.
8
Blood Targets of Adjuvant Drugs Against COVID19.抗新冠病毒辅助药物的血液靶点
J Blood Med. 2020 Jul 2;11:237-241. doi: 10.2147/JBM.S256121. eCollection 2020.

本文引用的文献

1
Response by Zhang et al to Letter Regarding Article, "Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19".张等人对关于文章《住院使用血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂与 COVID-19 住院高血压患者死亡率的关联》的信件的回复
Circ Res. 2020 Jun 5;126(12):e142-e143. doi: 10.1161/CIRCRESAHA.120.317242. Epub 2020 Jun 4.
2
Response to: Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan).对：中性内肽酶抑制剂 - 血管紧张素II受体阻滞剂组合（沙库巴曲/缬沙坦）的反应。
Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(4):252. doi: 10.1093/ehjcvp/pvaa035.
3
Prognostic value of NT-proBNP in patients with severe COVID-19.NT-proBNP 对重症 COVID-19 患者的预后价值。
Respir Res. 2020 Apr 15;21(1):83. doi: 10.1186/s12931-020-01352-w.
4
Neprilysin inhibitor-angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients.中性肽链内切酶抑制剂-血管紧张素II受体阻滞剂组合（沙库巴曲/缬沙坦）：应用于2019冠状病毒病患者的理论依据
Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(3):135-136. doi: 10.1093/ehjcvp/pvaa028.
5
Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension.新型冠状病毒肺炎疫情期间心血管疾病患者的肾素 - 血管紧张素系统抑制：小题大做？意大利高血压学会董事会董事及科学主任的活动声明
High Blood Press Cardiovasc Prev. 2020 Apr;27(2):105-108. doi: 10.1007/s40292-020-00380-3. Epub 2020 Apr 7.
6
Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?2019冠状病毒病（COVID-19）：血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂是否具有双相效应？
J Am Heart Assoc. 2020 Apr 7;9(7):e016509. doi: 10.1161/JAHA.120.016509. Epub 2020 Apr 1.
7
Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China.新冠肺炎住院患者中心脏损伤与死亡的相关性研究：中国武汉。
JAMA Cardiol. 2020 Jul 1;5(7):802-810. doi: 10.1001/jamacardio.2020.0950.
8
Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial.在PIONEER-HF试验中随机分配接受沙库巴曲缬沙坦或依那普利治疗的急性失代偿性心力衰竭患者的临床结局
Circulation. 2019 May 7;139(19):2285-2288. doi: 10.1161/CIRCULATIONAHA.118.039331.
9
Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.血管紧张素-脑啡肽酶抑制剂在急性失代偿性心力衰竭中的应用。
N Engl J Med. 2019 Feb 7;380(6):539-548. doi: 10.1056/NEJMoa1812851. Epub 2018 Nov 11.
10
Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis.联合使用 Neprilysin 和肾素-血管紧张素系统抑制剂治疗射血分数降低的心力衰竭：一项荟萃分析。
Eur J Heart Fail. 2016 Oct;18(10):1238-1243. doi: 10.1002/ejhf.603. Epub 2016 Jun 30.